This guide covers what is transferred, how the process runs, which commercial models exist, where transfers go wrong, and what hospitals, pharma companies, and biotech developers should settle before signing anything.
Key takeaways
- Technology transfer covers IP rights, process knowledge, analytical methods, quality systems, and people capability. Rights alone are not enough.
- The common failure point is tacit knowledge: what the developer’s team does without writing it down.
- Technical feasibility and regulatory permission are separate questions. A process that works in one country still needs approval in another.
- Licensing, technology transfer, joint ventures, and contract manufacturing are different structures with different risks.
- Cell and gene therapies are harder to transfer than most small molecules or conventional biologics, because the process is closely tied to the product and often to the individual patient.
Introduction
Biotechnology technology transfer is the structured movement of a product, process, and the know-how behind it from a developer to a receiving organization so the receiver can make, test, register, and use that product on its own. The transfer is more than a license or a document handover. It is complete only when the receiving site can reproduce the product to the agreed specifications, with its people, equipment, and quality system, under the regulations of its own country.
What technology transfer means in biotechnology
Two usages of the term are common, and they overlap.
The first is commercial or inter-organisational transfer: a university, biotech company or manufacturer passes a technology to another party, usually under a licence or collaboration agreement. This is what business development teams mean.
The second is manufacturing technology transfer: moving a process from development to commercial production, or from one site to another. This is what quality and operations teams mean. WHO guidance describes it as the documented process of passing knowledge and experience between development and manufacturing, or between manufacturing sites, to achieve a robust, reproducible product.
Cross-border projects involve both at once. A rights holder in one country licenses a platform, and a receiving organization in another builds a facility and trains staff to run it. This is the situation VectorGene works in, and it is where most of the difficulty sits.
What is actually transferred
Buyers often underestimate this list. A complete transfer typically includes:
Legal and commercial rights
- Patent licenses, know-how licenses, trademarks, and data rights
- Territory, field of use, and exclusivity terms
- Regulatory dossier access or rights of reference, where applicable
Technical package
- Manufacturing process description, parameters, and acceptable ranges
- Raw material specifications and approved suppliers
- Equipment lists and critical equipment settings
- Analytical methods, reference standards, and specifications
- Stability data and comparability data
- Development reports explaining why the process is designed as it is
Quality and compliance package
- SOPs, batch records, and deviation and change control procedures
- Validation protocols, including process, cleaning, and method validation
- Release criteria and quality agreements
People and capability
- Training of operators, QC analysts, QA, and facility staff
- On-site support during first runs
- Troubleshooting access after go-live
The last category decides most outcomes. Documents are easy to send. Competence takes longer to move.
The stages of a technology transfer
Projects vary, but most follow this sequence.
1. Opportunity assessment and technology selection
The receiving organization decides what it needs and whether a candidate's technology fits. Questions at this stage include: Is the product clinically validated, and for which indications? Is it approved anywhere, investigational, or still preclinical? What does the patient population in the receiving market need? Can the receiving country realistically support the infrastructure?
Do not treat a clinical trial registration as evidence of approval. They are different facts.
2. Due diligence
Due diligence should cover four areas:
- IP: ownership chain, freedom to operate, licenses from third parties, and any encumbrances
- Technical: process maturity, reproducibility, yields, and the quality of data
- Regulatory: the product’s status in its home jurisdiction and what the target regulator will expect
- Commercial: the counterparty’s capacity to support a transfer and the real cost of the program
Cross-border deals need extra care on authority to license and on export, import, and data-transfer rules.
3. Agreement and structure
Commercial terms are negotiated here: license scope, fees, royalties, milestones, supply arrangements, exclusivity, minimum commitments, IP improvements, and governance. See the models table below.
4. Gap analysis and facility planning
The receiving site’s facility, equipment, utilities, staff, and quality system are compared with what the process requires. This produces the infrastructure plan, the equipment list, the cleanroom classification requirements, and the training plan. Cost estimates become reliable only after this step.
5. Documentation and knowledge transfer
The sending party delivers process descriptions, methods, and quality documents. Good programs also run structured sessions where the developers' scientists explain the reasoning behind each step and the known risks, not just the steps.
6. Training and technical demonstration
Receiving staff are trained, usually at the source site first, then supported at the receiving site. Observed runs and hands-on practice matter more than lectures.
7. Engineering and process runs
Equipment is installed, qualified, and commissioned. The receiving site then runs engineering batches to show it can execute the process, followed by validation or consistency batches as required by the applicable regulator.
8. Analytical method transfer and comparability
Methods are verified at the receiving lab. The receiving site must show that its product is comparable to the source product on agreed quality attributes. For advanced therapies, comparability design needs early regulatory input.
9. Regulatory submission and clinical implementation
The regulator reviews the product and the site. Depending on the product and country, this may involve clinical trial approvals, bridging data, ethics committee reviews, and GMP inspections. Only after this does routine clinical or commercial use begin.
10. Post-transfer support and continuous improvement
Change control, trending, deviation review, and ongoing technical support from the originator continue after go-live. Agreements that stop at the first successful batch tend to run into trouble in year two.
Why cell and gene therapy transfers are different
For a conventional drug, the product can often be characterized thoroughly, so the process has some flexibility. Cell and gene therapies are different in several ways:
- The process is closely tied to the product. Small process changes can alter product quality in ways that are hard to detect.
- Starting material is variable. Autologous therapies start from each patient’s own cells.
- Shelf life can be short. Logistics, chain of identity, and chain of custody become part of the manufacturing design.
- Analytical methods are complex. Potency assays in particular are difficult to standardize and transfer.
- Operator skill matters more. Open or semi-closed steps depend on technique, so training carries real weight.
- Raw material supply can be a bottleneck. Vectors, reagents, and consumables may come from limited suppliers.
For these reasons, a cell or gene therapy technology transfer should plan for longer training, tighter comparability work, and early regulatory engagement than a standard biologic. A related article in this series covers the CAR-T case in detail.
Regulatory and GMP considerations
Technology transfer does not move regulatory approval with it. The receiving country’s regulator decides what is required. Planning should address:
- Product category and pathway: how the product is classified in the target country and which bodies are involved
- GMP standards: whether the receiving facility must meet national GMP rules, WHO, PIC/S-aligned, or other expectations
- Clinical evidence: whether existing foreign data is accepted, whether bridging studies are needed, and whether local trials are required
- Import and export rules: for materials, cells, vectors, and equipment
- Ethics and consent: local committee approval and patient consent requirements
In India, for example, advanced therapy projects may involve several authorities and committees, and their roles should be confirmed against current official documents before any plan is finalized. A dedicated article on this topic is planned in this cluster.
Useful international reference points include WHO guidance on technology transfer in pharmaceutical manufacturing, ICH Q8, Q9, Q10, and Q11 on development, risk management, pharmaceutical quality systems, and drug substance development, and ISPE guidance on technology transfer.
Where technology transfers fail
Most failures are predictable. The most common:
- Tacit knowledge is never captured. The originator’s team knows things the batch record does not say.
- The license was signed before the gap analysis. The receiving site then discovers that the facility or budget cannot support the process.
- Underestimated timelines. Procurement, qualification, hiring, and regulatory review run longer than planned.
- Weak quality agreements. Responsibilities for deviations, changes, and releases are not defined.
- Unclear IP on improvements. Local process improvements become a dispute later.
- Overreliance on one supplier. Raw materials or critical equipment become single points of failure.
- No plan for support after go-live. Staff turnover and the knowledge leave with them.
- Regulatory assumptions. Teams assume approval in one country supports approval in another.
A risk assessment run before signing and repeated at each stage catches many of these.
Cost and timeline: what to ask for
Reliable figures depend on the technology, the country, and the starting infrastructure, so any single number quoted without context should be treated with caution. A sound budget separates:
- Capital expenditure: facility fit-out, cleanrooms, equipment, qualification
- Technology costs: upfront fees, royalties, milestone payments
- Operating expenditure: staff, consumables, QC testing, maintenance, quality systems
- Regulatory and clinical costs: submissions, trials, inspections
- Transfer program costs: training, travel, consulting, and project management
Ask any partner for a phased budget with stated assumptions, and be wary of a single all-in figure presented early.
A practical checklist before you commit
- Is the technology’s regulatory status clear in its home country and in the target country?
- Does the agreement cover know-how, training, and support, or only IP?
- Has a gap analysis been completed on the receiving site?
- Are IP ownership, improvements, and sublicensing rights defined?
- Are supply terms for critical materials agreed?
- Is there a quality agreement and a change control process?
- Is there a regulatory strategy agreed with the relevant authority?
- Are milestones and payments linked to technical progress rather than calendar dates alone?
- What happens if the transfer fails or the partner exits?
Frequently asked questions
What is technology transfer in biotechnology?
It is the process of moving a biotechnology product or platform, together with the process knowledge and quality systems needed to make it, from one organization or site to another so the receiver can produce it independently and in compliance with applicable regulations.
What is the difference between technology licensing and technology transfer?
A license gives legal permission to use intellectual property. Technology transfer also moves the practical knowledge, methods, training, and site readiness needed to execute the process. A license can exist without a transfer, but a transfer almost always requires a license.
How long does a biotechnology technology transfer take?
It depends on product complexity, the receiving site’s readiness, and the regulatory pathway. Projects that require a new facility and regulatory review usually run for years rather than months. Any timeline should come from a site-specific gap analysis.
Who owns the intellectual property after a transfer?
Usually the originator keeps the core IP, and the receiver gets defined rights. Ownership of improvements made by the receiver is negotiable and should be stated in the agreement.
Does technology transfer include regulatory approval?
No. Approval is granted by the regulator in each country. A transfer can include support for regulatory strategy and documentation, but it does not guarantee approval.
Why is cell and gene therapy technology transfer harder than for small molecules?
Processes are complex, closely tied to product quality, and depend on variable biological starting material and skilled operators. Analytical methods and comparability are also harder to standardize.
What are typical costs?
Costs vary widely and should be built from a site-specific plan. Separate capital, technology, operating, regulatory, and program costs, and treat any early single-figure estimate as illustrative.
Conclusion
A successful biotechnology technology transfer is an exercise in building capability, not buying a product. The legal agreement matters, but so do the facility, the people, the quality system, and the regulatory plan. Organizations that run gap analysis before signing, define support after go-live, and keep technical feasibility separate from regulatory permission tend to avoid the failures described above.
For hospitals and pharma companies in India and wider Asia, the practical question is almost always whether a technology exists. The question is whether the local organization can implement it safely, legally, and sustainably, and what it will take to get there.
Exploring Technology Transfer?
VectorGene Biotech Limited supports hospitals, pharmaceutical manufacturers, biotechnology companies, and research institutions in evaluating technology transfer, licensing, and localization opportunities across advanced biomedical platforms. Technology availability and licensing rights are partner-specific and subject to confirmation.
Learn more at vectorgene.hk/technology-transfer.html or contact partnerships@vectorgene.hk.
Sandeep Kumar Wamne
Founder - VectorGene Biotech Limited
